Skip to content

HCW Biologics Inc.: 10-Q filed 2023-08-11

What HCW Biologics Inc. reported in its quarterly report filed 2023-08-11 (fiscal Q2 2023): 37 published measures, 104 facts as tagged in accession 0000950170-23-041607.

This filing

Form
10-Q (quarterly report)
Filed
2023-08-11
Fiscal period
fiscal Q2 2023
Accession
0000950170-23-041607 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All HCW Biologics Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2023-06-3039,483,244USD
At 2022-12-3146,809,155USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2023-06-3010,897,602USD
At 2022-12-319,380,649USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2023-06-3028,585,642USD
At 2023-03-3132,618,927USD
At 2022-12-3137,428,506USD
At 2022-06-3046,165,428USD
At 2022-03-3149,398,654USD
At 2021-12-3151,193,240USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2023-06-307,449,010USD
At 2022-12-3122,326,356USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-4,304,420USD91
2023-01-01 to 2023-06-30-9,375,106USD181
2023-01-01 to 2023-03-31-5,070,686USD90
2022-04-01 to 2022-06-30-3,510,561USD91
2022-01-01 to 2022-06-30-5,567,768USD181
2022-01-01 to 2022-03-31-2,057,207USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2023-01-01 to 2023-06-30-13,030,059USD181
2022-01-01 to 2022-06-30-4,281,998USD181

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2023-01-01 to 2023-06-301,856,900USD181
2022-01-01 to 2022-06-3036,461USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2023-01-01 to 2023-06-309,613USD181
2022-01-01 to 2022-06-308,273USD181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2023-01-01 to 2023-06-30-1,856,900USD181
2022-01-01 to 2022-06-307,963,379USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2023-06-30-54,913,152USD
At 2022-12-31-45,538,046USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2023-04-01 to 2023-06-3035,910,669shares91
2023-01-01 to 2023-06-3035,897,224shares181
2022-04-01 to 2022-06-3035,814,482shares91
2022-01-01 to 2022-06-3035,796,257shares181

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2023-04-01 to 2023-06-3035,910,669shares91
2023-01-01 to 2023-06-3035,897,224shares181
2022-04-01 to 2022-06-3035,814,482shares91
2022-01-01 to 2022-06-3035,796,257shares181

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-0.12USD/shares91
2023-01-01 to 2023-06-30-0.26USD/shares181
2022-04-01 to 2022-06-30-0.1USD/shares91
2022-01-01 to 2022-06-30-0.16USD/shares181

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-0.12USD/shares91
2023-01-01 to 2023-06-30-0.26USD/shares181
2022-04-01 to 2022-06-30-0.1USD/shares91
2022-01-01 to 2022-06-30-0.16USD/shares181

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2023-01-01 to 2023-06-300USD181
2022-01-01 to 2022-12-310USD365

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2023-06-3012,623,308USD
At 2022-12-3110,804,610USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2023-01-01 to 2023-06-30522,629USD181
2022-01-01 to 2022-06-30531,683USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-4,510,521USD91
2023-01-01 to 2023-06-30-9,871,091USD181
2022-04-01 to 2022-06-30-3,511,077USD91
2022-01-01 to 2022-06-30-5,391,886USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2023-06-3019,799,166USD
At 2022-12-3134,070,919USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2023-04-01 to 2023-06-3095,514USD91
2023-01-01 to 2023-06-30188,951USD181
2022-04-01 to 2022-06-300USD91
2022-01-01 to 2022-06-300USD181

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2023-06-304,537,898USD
At 2022-12-312,956,481USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2023-06-302,116,216USD
At 2022-12-311,226,156USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2023-04-01 to 2023-06-304,630,926USD91
2023-01-01 to 2023-06-3010,004,029USD181
2022-04-01 to 2022-06-303,677,877USD91
2022-01-01 to 2022-06-307,348,155USD181

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2023-04-01 to 2023-06-30120,405USD91
2023-01-01 to 2023-06-30132,938USD181
2022-04-01 to 2022-06-30166,800USD91
2022-01-01 to 2022-06-301,956,269USD181

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2023-04-01 to 2023-06-30502,402USD91
2023-01-01 to 2023-06-30531,752USD181
2022-04-01 to 2022-06-30287,200USD91
2022-01-01 to 2022-06-301,615,276USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2023-04-01 to 2023-06-301,616,666USD91
2023-01-01 to 2023-06-303,872,479USD181
2022-04-01 to 2022-06-301,969,882USD91
2022-01-01 to 2022-06-303,759,558USD181

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2023-06-307,449,010USD
At 2022-12-3122,326,356USD
At 2022-06-3015,420,331USD
At 2021-12-3111,730,677USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2023-06-3083,495,201USD
At 2022-12-3182,962,964USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2023-06-30110,561USD

Long-term debt

Long-term borrowings under this concept, which can include the current portion depending on presentation. It is not total liabilities and may exclude leases and other obligations.

PeriodValueUnitDays
At 2023-06-306,359,704USD
At 2022-12-316,409,893USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2023-06-30211,019USD
At 2022-12-31333,875USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2023-04-01 to 2023-06-303,014,260USD91
2023-01-01 to 2023-06-306,131,550USD181
2022-04-01 to 2022-06-301,707,995USD91
2022-01-01 to 2022-06-303,588,597USD181

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2023-01-01 to 2023-06-30583,180USD181
2022-01-01 to 2022-06-30292,363USD181

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2023-01-01 to 2023-06-30188,951USD181
2022-01-01 to 2022-06-300USD181

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2023-01-01 to 2023-06-309,613USD181
2022-01-01 to 2022-06-308,273USD181

Operating lease payments

Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.

PeriodValueUnitDays
2023-01-01 to 2023-06-3084,040USD181

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2023-01-01 to 2023-06-30289,516USD181
2022-01-01 to 2022-06-30213,934USD181

Inspect the source

Entity
HCW Biologics Inc. / CIK 0001828673
Captured
2026-09-21T17:29:55.000Z
SEC response SHA-256
ec2f89184d2effc79bd61262508df1bb4955251bd9c779b166cb9345b80a8cfa

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001828673.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))